Emerging Therapies Underscore Need for Genomic Testing in HR+/HER2– Breast Cancer
Kari Wisinski, MD, highlights the use of oral selective estrogen receptor degraders and CDK4/6 inhibitors in the treatment of patients with hormone receptor–positive/HER2-negative breast cancer, the growing role of antibody-drug conjugates across the breast cancer spectrum, and ongoing research taking place at Carbone Cancer Center.
Dr Chaudhary on the Utilization of Trastuzumab Deruxtecan in Metastatic HER2+ Breast Cancer
September 29th 2023Lubna Chaudhary, MD, MS, discusses the ongoing investigation and utilization of trastuzumab deruxtecan in patients with metastatic HER2-positive breast cancer and compared this agent’s efficacy with that of trastuzumab emtansine.
Multiple Myeloma: Unmet Needs and Future Directions in Care
After discussing earlier-line use of CAR T-cell therapy in patients with multiple myeloma, the panel considers key takeaways and future evolutions in the treatment landscape.
CAR T-Cell Therapy in Multiple Myeloma: Updates from ASCO 2023 and Beyond
Before closing out their discussion on novel therapies in multiply relapsed multiple myeloma, panelists identify the evolving role of CAR T-cell therapy.
Combination Strategies With Bispecifics in Multiple Myeloma
Key opinion leaders on multiple myeloma reflect on the use of combination strategies with bispecifics in the multiply relapsed setting.
Bispecifics in Multiple Myeloma: Dosing and Transition of Care
A brief review of logistical considerations that play a part in selecting novel therapy for patients with multiply relapsed multiple myeloma.
Multiple Myeloma: Sequencing Novel Therapies in Later Lines of Treatment
Focused discussion on the sequencing of bispecifics or CAR T-cell therapies in patients with multiply relapsed multiple myeloma.
Patient Scenario: Bispecifics in MM After Multiple Prior Lines of Therapy
Centering discussion on a patient scenario of multiply relapsed multiple myeloma, panelists consider available novel therapies within the treatment landscape.
Factors in Selecting Therapy at First Relapse in Multiple Myeloma
Shared insight from experts in multiple myeloma on patient and disease characteristics that inform selection of best therapy at first relapse.
Patient Scenario: Treatment Options in MM at First Relapse
Key opinion leaders review the case of a patient at first relapse with multiple myeloma and consider optimal treatment strategies in this setting.
Treatment Duration in Patients With Newly Diagnosed Multiple Myeloma
A panel of experts reflects on treatment duration and its role in optimizing management of patients with newly diagnosed multiple myeloma.
Determining Frailty in Patients With Newly Diagnosed Multiple Myeloma
Focused discussion on the importance of patient frailty in determining optimal treatment pathways in newly diagnosed multiple myeloma.
Treatment Options for Transplant-Ineligible Newly Diagnosed Multiple Myeloma
Expert perspectives on the treatment armamentarium for transplant-ineligible newly diagnosed multiple myeloma.
Impact of Risk Status on Treatment Pathways in Newly Diagnosed Multiple Myeloma
Shared insight on the impact risk status has on the selection of optimal therapy for patients with newly diagnosed multiple myeloma.
Induction Therapy Regimens for Transplant-Eligible NDMM
Key opinion leaders on multiple myeloma management review available induction therapy regimens in the transplant-eligible setting.
NDMM: Identifying Patient and Disease Factors to Select Appropriate Therapy
Comprehensive insight on patient and disease characteristics that help to inform best available therapy for patients with newly diagnosed multiple myeloma.
What is the Role of Transplant in Newly Diagnosed Multiple Myeloma?
Expert panelists reflect on the continuing role of stem cell transplant in patients with newly diagnosed multiple myeloma.